bioRxivMicrobiologyPreprint
In vitro infection of human lung tissue with SARS-CoV-2: Heterogeneity in host defense and therapeutic response
M. A. Schaller, Y. Sharma, Z. Dupee, D. T. Nguyen, J. M. Uruena, R. A. Smolcheck, J. C. Loeb, T. N. Machuca, J. A. Lednicky, D. Odde, R. F. Campbell, W. G. Sawyer, B. Mehrad
Abstract
Cell lines are the mainstay in understanding the biology of COVID-19 infection, but do not recapitulate many of the complexities of human infection. The use of human lung tissue is one solution for the study of such novel respiratory pathogens. We hypothesized that a cryopreserved bank of human lung tissue allows for the in vitro study of the inter-individual heterogeneity of host response to SARS-CoV-2 infection, thus providing a bridge between studies with cell lines and studies in animal models. We generated a cryobank of tissues from 16 donors, most of whom had risk factors for severe illness from COVID-19. Cryopreserved tissues preserved 90% of cell viability and contained heterogeneous populations of metabolically active epithelial, endothelial, and immune cell subsets of the human lung. Samples were readily infectible with HCoV-OC43 and SARS-CoV-2 coronavirus strains, and demonstrated comparable susceptibility to infection. In contrast, we observed a marked donor-dependent heterogeneity in the expression of IL-6, CXCL8 and IFN{beta} in response to SARS-CoV-2 infection. Treatment of tissues with dexamethasone and the experimental drug, N-hydroxycytidine, suppressed viral growth in all samples, whereas chloroquine and remdesivir had no detectable effect. Metformin and sirolimus, molecules with predicted antiviral activity, suppressed viral replication in tissues from a subset of donors. In summary, we developed a novel system for the in vitro study of human SARS-CoV-2 infection using primary human lung tissue from a library of donor tissues. This model may be useful for drug screening and for understanding basic mechanisms of COVID-19 pathogenesis. ImportanceThe current biological systems for the study of COVID-19 are in vitro systems that differ from the human lung in many respects, and animal hosts to which the virus is not adapted. We developed another alternative for studying pathogenesis and drug susceptibility of SARS-CoV-2 in a cryopreserved bank of human lung tissues. We consider the importance of this work to relate to the practical use of this culture system as a repeatable and scalable approach that allows for the study of an important infection in relevant tissues. The tissue bank highlights the heterogeneous response to SARS-CoV-2 infection and treatment, which allows researchers to investigate why treatments work in some donors but not others.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An ex vivo human precision-cut lung slice platform provides insight into SARS-CoV-2 pathogenesis and antiviral drug efficacy
X. Zhang, R. D. Pechous, … J. L. Kennedy·bioRxiv·Apr 18, 2023
- Impact of cell culture model systems on SARS-CoV-2 and MERS-CoV infection dynamics and antiviral responses
Kim Lam Chiok, Mark E. Fenton, … Arinjay Banerjee·bioRxiv·Feb 24, 2025
- Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells
J. Grau-Exposito, D. Perea, … M. J. Buzon·bioRxiv·Apr 21, 2021
- SARS-CoV-2 Infection of Pluripotent Stem Cell-derived Human Lung Alveolar Type 2 Cells Elicits a Rapid Epithelial-Intrinsic Inflammatory Response
Jessie Huang, Adam J. Hume, … Darrell N. Kotton·Cell stem cellPeer-reviewed·Sep 18, 2020
- A human disease model of SARS-CoV-2-induced lung injury and immune responses with a microengineered organ chip
M. Zhang, P. Wang, … J. Qin·Advanced SciencePeer-reviewed·Dec 21, 2020
- A novel model demonstrating that human immune cells promote multiorgan SARS-CoV-2 dissemination and human T cells limit anti-viral innate immunity
Amber N. Wolabaugh, Vrushali V. Agashe, … Megan Sykes·bioRxiv·Jun 19, 2026